Furthermore, ferroptosis inhibitors, TRF, and ECH1 which take ferroptosis as target have been confirmed to have great potential in the treatment of NAFLD in many animal studies (26, 126, 130, 149, 150). This evidence concerns the gene ECH1 and metabolic dysfunction-associated steatotic liver disease.